These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1624 related items for PubMed ID: 8509225

  • 1. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
    Cheung NK, Canete A, Cheung IY, Ye JN, Liu C.
    Int J Cancer; 1993 May 28; 54(3):499-505. PubMed ID: 8509225
    [Abstract] [Full Text] [Related]

  • 2. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
    Ye JN, Cheung NK.
    Int J Cancer; 1992 Jan 21; 50(2):197-201. PubMed ID: 1730513
    [Abstract] [Full Text] [Related]

  • 3. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
    Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, Heller G, Larson SM.
    Cancer Res; 1994 Apr 15; 54(8):2228-33. PubMed ID: 8174131
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
    Saito M, Yu RK, Cheung NK.
    Biochem Biophys Res Commun; 1985 Feb 28; 127(1):1-7. PubMed ID: 2579648
    [Abstract] [Full Text] [Related]

  • 6. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB, Förster-Waldl E, Brämswig KH, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E.
    Eur J Immunol; 2006 May 28; 36(5):1267-74. PubMed ID: 16568495
    [Abstract] [Full Text] [Related]

  • 7. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
    Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M.
    Clin Cancer Res; 1997 Nov 28; 3(11):1969-76. PubMed ID: 9815586
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
    Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF.
    J Immunol; 1993 Sep 15; 151(6):3390-8. PubMed ID: 8376782
    [Abstract] [Full Text] [Related]

  • 10. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
    Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO.
    Cancer Res; 1998 Jul 01; 58(13):2844-9. PubMed ID: 9661900
    [Abstract] [Full Text] [Related]

  • 11. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
    Kushner BH, Kramer K, Modak S, Cheung NK.
    J Clin Oncol; 2011 Mar 20; 29(9):1168-74. PubMed ID: 21343563
    [Abstract] [Full Text] [Related]

  • 12. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.
    Cheung NK, Neely JE, Landmeier B, Nelson D, Miraldi F.
    J Nucl Med; 1987 Oct 20; 28(10):1577-83. PubMed ID: 3655911
    [Abstract] [Full Text] [Related]

  • 13. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.
    Vázquez AM, Pérez A, Hernández AM, Macías A, Alfonso M, Bombino G, Pérez R.
    Hybridoma; 1998 Dec 20; 17(6):527-34. PubMed ID: 9890708
    [Abstract] [Full Text] [Related]

  • 14. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
    Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, Cheung NK.
    Cancer Res; 1987 Oct 15; 47(20):5377-81. PubMed ID: 3115567
    [Abstract] [Full Text] [Related]

  • 15. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y.
    Int J Cancer; 2013 Aug 01; 133(3):757-65. PubMed ID: 23354868
    [Abstract] [Full Text] [Related]

  • 16. Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2.
    Patel K, Rossell RJ, Pemberton LF, Cheung NK, Walsh FS, Moore SE, Sugimoto T, Kemshead JT.
    Br J Cancer; 1989 Dec 01; 60(6):861-6. PubMed ID: 2481486
    [Abstract] [Full Text] [Related]

  • 17. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):194-6. PubMed ID: 11464881
    [Abstract] [Full Text] [Related]

  • 18. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D.
    Cancer Res; 2005 Apr 15; 65(8):3410-8. PubMed ID: 15833876
    [Abstract] [Full Text] [Related]

  • 19. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Cheung NK, Modak S.
    Clin Cancer Res; 2002 May 15; 8(5):1217-23. PubMed ID: 12006541
    [Abstract] [Full Text] [Related]

  • 20. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
    Uttenreuther-Fischer MM, Krüger JA, Fischer P.
    J Immunol; 2006 Jun 15; 176(12):7775-86. PubMed ID: 16751426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.